Sfoglia per AUTORE
BRINGHEN S
Collezione AOU Città della Salute di Torino

  

Items : 95

2025
AOU Città della Salute di Torino
AOU Novara

Quaresima M; Barbieri E; D'Arrigo G; Reddiconto G; Tripepi G; Morè S; Sica A; Mele G; Falcone AP; Mancuso K; Cangialosi C; Farina G; Vincelli ID; Paris L; Mina R; Fazio F; Bruzzese A; Vigna E; Della Pepa R; Mele A; Musso M; Palmieri S; Zamagni E; Conticello C; Bolli N; Pettine L; Petrucci MT; De Magistris C; Lotti F; et alii...

Blood pressure variability as predictor of cancer therapy-related cardiovascular toxicity in patients with Multiple Myeloma. in Hypertension research : official journal of the Japanese Society of Hypertension / Hypertens Res. 2025 Jan 22. doi: 10.1038/s41440-024-02084-w.
2025
ASL Città di Torino
AOU Città della Salute di Torino

Veglio F; Gay F; Bringhen S; Rabbia F; Leone D; Paladino A; Cesareo M; Colomba A; Votta S; Catarinella C; Mingrone G; Astarita A; Airale L; Fanelli E; Picca G; Milan A; Vallelonga F;

Impact of daratumumab on collection and engraftment in multiple myeloma patients undergoing hematopoietic stem cell mobilization with G-CSF plus on-demand plerixafor. in Bone marrow transplantation / Bone Marrow Transplant. 2025 Jan;60(1):79-82. doi: 10.1038/s41409-024-02432-x. Epub 2024 Oct 4.
2025
AOU Città della Salute di Torino

Bringhen S; Santoro A; Bruno B; Lorenzi M; Francisci T; Benevolo G; De Philippis C; Mannina D; Larocca A; Taurino D; Oliva S; D'agostino M; Mariotti J; Mercadante S; Gay F; Sarina B; Casson A; Garibaldi B; Bertuglia G; Mina R; Bramanti S;

M-protein-related necrobiotic granuloma in a multiple myeloma patient treated with daratumumab, lenalidomide and dexamethasone. in British journal of haematology / Br J Haematol. 2025 Jan;206(1):16-17. doi: 10.1111/bjh.19887. Epub 2024 Nov 14.
2025
AOU Città della Salute di Torino

D'Agostino M; Impalà GA; Bruno B; Bringhen S; Bertuglia G;

Haemodynamic Forces: Emerging Markers of Ventricular Remodelling in Multiple Myeloma Cardiovascular Baseline Risk Assessment. in Cancers / Cancers (Basel). 2024 Sep 4;16(17):3081. doi: 10.3390/cancers16173081.
2024
AOU Città della Salute di Torino

Colomba A; Astarita A; Mingrone G; Airale L; Catarinella C; Vallelonga F; Leone D; Cesareo M; Paladino A; Bringhen S; Gay F; Pedrizzetti G; Veglio F; Milan A;

Risk of Infection in Patients With Multiple Myeloma Treated With T-Cell Redirecting Approaches: A Call Out for Clinicians. in Clinical lymphoma, myeloma & leukemia / Clin Lymphoma Myeloma Leuk. 2024 Sep;24(9):592-603. doi: 10.1016/j.clml.2024.05.002. Epub 2024 May 4
2024
AOU Città della Salute di Torino

Mina R; Corcione S; Mikulska M; Bruno B; De Rosa FG; Bringhen S; Lupia T; Cani L;

2024
AOU Città della Salute di Torino

Legenne P; Zitt C; Dawson KM; Stumpp MT; Suter C; Pour L; Iversen KF; Gamberi B; Khandanpour C; Vacca A; Jurczyszyn A; Trautmann-Grill K; Bringhen S; Grz??ko N; Szarejko M; Knop S; Stavropoulou V; Fey MF; Leupin N; Goldschmidt H;

2024
AOU Città della Salute di Torino

Colomba A; Astarita A; Mingrone G; Airale L; Catarinella C; Vallelonga F; Leone D; Cesareo M; Paladino A; Bringhen S; Gay F; Pedrizzetti G; Veglio F; Milan A;

30-Minute infusion of isatuximab in patients with newly diagnosed multiple myeloma: Results of a Phase 1b study analysis. in HemaSphere / Hemasphere. 2024 Nov 5;8(11):e70041. doi: 10.1002/hem3.70041. eCollection 2024 Nov.
2024
AOU Città della Salute di Torino

Ocio EM; Perrot A; Moreau P; Mateos MV; Bringhen S; Martínez-López J; Karlin L; Wang SY; Oprea C; Li Y; Kodas E; San-Miguel J;

Belantamab mafodotin in triple-refractory multiple myeloma patients: A retro-prospective observational study in Italy. in EJHaem / EJHaem. 2024 Apr 30;5(3):485-493. doi: 10.1002/jha2.907. eCollection 2024 Jun.
2024
AOU Città della Salute di Torino

Derudas D; Gamberi B; Musto P; De Stefano V; Renzo ND; Conticello C; Antonioli E; Bringhen S; Belotti A; Zambello R; Tacchetti P; Musso M; Piciocchi A; Della Pepa R; Corvatta L; Petrucci MT; Fazio F; Boccadoro M; Offidani M; Morè S;

Anti-BCMA CAR-T cell-based therapies and bispecific antibodies in the immunotherapy era: are we ready for this? in Expert review of hematology / Expert Rev Hematol. 2024 Jul;17(7):375-390. doi: 10.1080/17474086.2024.2357274. Epub 2024 May 21.
2024
AOU Città della Salute di Torino

Zamagni E; Bringhen S; Pezzatti S; Mangiacavalli S; Malerba L; Della Pepa R; Aquino S; Antonioli E; Gamberi B; Martino M;

An atypical presentation of visceral leishmaniasis mimicking multiple myeloma relapse. in American journal of hematology / Am J Hematol. 2024 Jan;99(1):137-141. doi: 10.1002/ajh.27147. Epub 2023 Nov 20.
2024
AOU Città della Salute di Torino

Bruno B; Maletta F; Bringhen S; Benevolo G; Bertuglia G;

Daratumumab or Active Monitoring for High-Risk Smoldering Multiple Myeloma. in The New England journal of medicine / N Engl J Med. 2024 Dec 9. doi: 10.1056/NEJMoa2409029.
2024
AOU Città della Salute di Torino

Dimopoulos MA; Voorhees PM; Schjesvold F; Cohen YC; Hungria V; Sandhu I; Lindsay J; Baker RI; Suzuki K; Kosugi H; Levin MD; Beksac M; Stockerl-Goldstein K; Oriol A; Mikala G; Garate G; Theunissen K; Spicka I; Mylin AK; Bringhen S; Uttervall K; Pula B; Medvedova E; Cowan AJ; Moreau P; Mateos MV; Goldschmidt H; Ahmadi T; Sha L; et alii...

New Strategies for the Treatment of Older Myeloma Patients. in Cancers / Cancers (Basel). 2023 May 10;15(10):2693. doi: 10.3390/cancers15102693.
2023
AOU Città della Salute di Torino

Larocca A; Cani L; Bertuglia G; Bruno B; Bringhen S;

2023
AOU Città della Salute di Torino

Ocio EM; Perrot A; Bories P; San-Miguel JF; Blau IW; Karlin L; Martinez-Lopez J; Wang SY; Bringhen S; Marcatti M; Mateos MV; Rodriguez-Otero P; Oliva S; Nogai A; Le Roux N; Dong L; Macé S; Gassiot M; Fitzmaurice T; Oprea C; Moreau P;

Ixazomib Versus Placebo as Postinduction Maintenance Therapy in Newly Diagnosed Multiple Myeloma Patients: An Analysis by Age and Frailty Status of the TOURMALINE-MM4 Study. in Clinical lymphoma, myeloma & leukemia / Clin Lymphoma Myeloma Leuk. 2023 Jul;23(7):491-504. doi: 10.1016/j.clml.2023.03.007. Epub 2023 Mar 2
2023
AOU Città della Salute di Torino

Cain LE; Manne S; Rajkumar SV; Cherepanov D; Wang B; Vorog A; Labotka RJ; C de Farias DL; Min CK; Grosicki S; Benjamin R; Pour L; Bringhen S; Dimopoulos MA;

The prevalence and outcomes of frail older adults in clinical trials in multiple myeloma: A systematic review. in Blood cancer journal / Blood Cancer J. 2023 Jan 5;13(1):6. doi: 10.1038/s41408-022-00779-2.
2023
AOU Città della Salute di Torino

Mian H; McCurdy A; Giri S; Grant S; Rochwerg B; Winks E; Rosko AE; Engelhardt M; Pawlyn C; Cook G; Jackson G; Bringhen S; Facon T; Larocca A; Zweegman S; Wildes TM;

2023
AOU Città della Salute di Torino

Astarita A; Mingrone G; Airale L; Cesareo M; Colomba A; Catarinella C; Leone D; Gay F; Bringhen S; Veglio F; Milan A; Vallelonga F;

2023
AOU Città della Salute di Torino

Mingrone G; Astarita A; Colomba A; Catarinella C; Cesareo M; Airale L; Paladino A; Leone D; Vallelonga F; Bringhen S; Gay F; Veglio F; Milan A;

2023
AOU Città della Salute di Torino

Ocio EM; Bringhen S; Martinez-Lopez J; San-Miguel J; Oliva S; Rodriguez-Otero P; Le Roux N; Dong Y; Doroumian S; Macé S; Mateos MV;

2022
AOU Città della Salute di Torino

Zamagni E; Bringhen S; Consoli U; Frigeri F; Pompa A; Tripepi G; Gamberi B; Gagliardi A; Gangemi D; Ballanti S; Martino M; Stocchi R; Cupelli L; Bonalumi A; Sgherza N; Vincelli D; Botta C; Mimmi S; Iaccino E; Vigna E; Mendicino F; Curci P; Uccello G; Criscuolo C; Belotti A; Cerchione C; Cascavilla N; Palumbo G; Pietrantuono G; et alii...

Evaluation of isatuximab in patients with soft-tissue plasmacytomas: An analysis from ICARIA-MM and IKEMA. in Leukemia research / Leuk Res. 2022 Nov;122:106948. doi: 10.1016/j.leukres.2022.106948. Epub 2022 Sep 6.
2022
AOU Città della Salute di Torino

Rawlings AM; Moreau P; Symeonidis A; Martin T; Mikala G; Jelínek T; Bringhen S; Hajek R; Spicka I; Beksac M; van de Velde H; Richardson PG;

Isatuximab plus pomalidomide and dexamethasone in elderly patients with relapsed/refractory multiple myeloma: ICARIA-MM subgroup analysis. in Haematologica / Haematologica. 2022 Mar 1;107(3):774-775. doi: 10.3324/haematol.2021.279160.
2022
AOU Città della Salute di Torino

Schjesvold F; Richardson PG; Facon T; Alegre A; Spencer A; Jurczyszyn A; Sunami K; Frenzel L; Min CK; Guillonneau S; Lin PL; Le-Guennec S; Campana F; Van de Velde H; Bensfia S; Bringhen S;

Adjusted comparison between elotuzumab and carfilzomib in combination with lenalidomide and dexamethasone as salvage therapy for multiple myeloma patients. in European journal of haematology / Eur J Haematol. 2022 Mar;108(3):178-189. doi: 10.1111/ejh.13723. Epub 2021 Nov 9.
2022
AOU Città della Salute di Torino

Musso M; De Stefano V; Musto P; Rizzello I; Barone M; Farina G; Reddiconto G; Cangialosi C; Pia Falcone A; Frigeri F; Tripepi G; Ballanti S; Cascavilla N; Garibaldi B; Rocchi S; Pantani L; Mele A; Bruzzese A; Botta C; Vigna E; Antonia Martino E; Mele G; Donatella Vincelli I; Tacchetti P; Catalano L; Ria R; Rossi E; Derudas D; Galli M; et alii...

Cost efficiency and effectiveness of biosimilar filgrastim in autologous transplant. in Bone marrow transplantation / Bone Marrow Transplant. 2022 Feb;57(2):312-314. doi: 10.1038/s41409-021-01541-1. Epub 2021 Nov 30.
2022
AOU Città della Salute di Torino

Tassi V; Evangelista A; Francisci T; Cattel F; Leone S; Bringhen S; Cavallo F; Ferrero D; Massaia M; Lia G; Omedè P; Redoglia V; Cerrano M; Scaldaferri M; Londono JS; Brunello L; Giaccone L; Boccadoro M; Bruno B;

Safety of Rapid Daratumumab Infusion: A Retrospective, Multicenter, Real-Life Analysis on 134 Patients With Multiple Myeloma. in Frontiers in oncology / Front Oncol. 2022 Mar 14;12:851864. doi: 10.3389/fonc.2022.851864. eCollection 2022.
2022
AOU Città della Salute di Torino

Bonello F; Rocchi S; Barilà G; Sandrone M; Talarico M; Zamagni E; Scaldaferri M; Vedovato S; Bertiond C; Pavan L; Bringhen S; Cattel F; Zambello R; Cavo M; Mina R;

2022
AOU Città della Salute di Torino

De Stefano V; Musto P; Gamberi B; Curci P; Mimmi S; Rizzello I; Iaccino E; Barone M; Farina G; Reddiconto G; Cangialosi C; Falcone AP; Frigeri F; Tripepi G; Ballanti S; Cascavilla N; Garibaldi B; Rocchi S; Pantani L; Mele A; Botta C; Mendicino F; Bruzzese A; Martino EA; Vigna E; Mele G; Vincelli ID; Tacchetti P; Catalano L; et alii...

In search of the optimal proteosome inhibitor. How, when and for whom? in Haematologica / Haematologica. 2021 Oct 1;106(10):2539-2541. doi: 10.3324/haematol.2021.278838.
2021
AOU Città della Salute di Torino

Engelhardt M; Bringhen S; Moreau P; Wäsch R; Waldschmidt J;

Isatuximab plus pomalidomide and dexamethasone in frail patients with relapsed/refractory multiple myeloma: ICARIA-MM subgroup analysis. in American journal of hematology / Am J Hematol. 2021 Nov 1;96(11):E423-E427. doi: 10.1002/ajh.26319. Epub 2021 Sep 23.
2021
AOU Città della Salute di Torino

Schjesvold F; Bringhen S; G Richardson P; Perrot A; Leleu X; Moreau P; A Dimopoulos M; Hulin C; Tekle C; Foster MC; Poole EM; van de Velde H; Facon T;

2021
AOU Città della Salute di Torino

Bringhen S; Pour L; Vorobyev V; Vural F; Warzocha K; Benboubker L; Koh Y; Maisnar V; Karlin L; Pavic M; Campana F; Le Guennec S; Menas F; van de Velde H; Richardson PG;

Isatuximab as monotherapy and combined with dexamethasone in patients with relapsed/refractory multiple myeloma. in Blood / Blood. 2021 Mar 4;137(9):1154-1165. doi: 10.1182/blood.2020008209.
2021
AOU Città della Salute di Torino

Anttila P; Capra M; Bringhen S; Dimopoulos M; Cavo M; Cole C; Gasparetto C; Hungria V; Jenner M; Vorobyev V; Ruiz EY; Yin JY; Saleem R; Hellet M; Macé S; Paiva B; Vij R;

2021
AOU Alessandria
AOU Città della Salute di Torino

Tacchetti P; Corradini P; Caravita di Toritto T; Patriarca F; Pompa A; Monaco F; Cellini C; Rota-Scalabrini D; Antonioli E; Bernardini A; Giuliani N; Galli M; Marasca R; Tosi P; Benevolo G; Capra A; Cascavilla N; Offidani M; Gaidano G; D'Agostino M; Bonello F; Larocca A; Boccadoro M; Bringhen S;

Melflufen plus dexamethasone in relapsed/refractory multiple myeloma: long-term survival follow-up from the Phase II study O-12-M1. in British journal of haematology / Br J Haematol. 2021 Jun;193(6):1105-1109. doi: 10.1111/bjh.17302. Epub 2021 Jan 6.
2021
AOU Città della Salute di Torino

Byrne C; Nordström E; Sonneveld P; Reeves B; Mellqvist UH; Plesner T; Voorhees PM; Bringhen S; Harmenberg J; Obermüller J; Richardson PG;

2021
AOU Città della Salute di Torino

Gentile M; Specchia G; Derudas D; Galli M; Botta C; Rocco S; Conticello C; Califano C; Giuliani N; Mangiacavalli S; Attingenti E; Lombardo A; Brunori M; Rossi E; Antonioli E; Ria R; Zambello R; Di Renzo N; Mele G; Marcacci G; Musto P; Capalbo S; Cascavilla N; Cerchione C; Belotti A; Criscuolo C; Uccello G; Curci P; Vigna E; et alii...

Recommendations for vaccination in multiple myeloma: a consensus of the European Myeloma Network. in Leukemia / Leukemia. 2021 Jan;35(1):31-44. doi: 10.1038/s41375-020-01016-0. Epub 2020 Aug 19.
2021
AOU Città della Salute di Torino

van de Donk N; Leleu X; Engelhardt M; Garderet L; Jackson G; Weisel K; Caers J; Delforge M; Mateos MV; Einsele H; Mohty M; Zojer N; Terpos E; Avet-Loiseau H; Gay F; Dimopoulos MA; Hajek R; Facon T; Driessen C; Zweegman S; Pawlyn C; San-Miguel J; Cavo M; Moreau P; Boccadoro M; Ludwig H; Goldschmidt H; Beksac M; Nijhof I; et alii...

A longitudinal analysis of chromosomal abnormalities in disease progression from MGUS/SMM to newly diagnosed and relapsed multiple myeloma. in Annals of hematology / Ann Hematol. 2021 Feb;100(2):437-443. doi: 10.1007/s00277-020-04384-w. Epub 2021 Jan 3.
2021
AOU Città della Salute di Torino

Oliva S; De Paoli L; Ruggeri M; Caltagirone S; Troia R; Oddolo D; D'Agostino M; Gilestro M; Mina R; Saraci E; Margiotta Casaluci G; Genuardi E; Bringhen S; Boccadoro M; Omedé P;

2021
AOU Alessandria
AO Cuneo
AOU Città della Salute di Torino

Larocca A; Corradini P; Monaco F; Boccadoro M; Ballanti S; Offidani M; De Paoli L; De Sabbata G; Aquino S; Paris L; Grasso M; Belotti A; Cellini C; Tacchetti P; Zambello R; Musolino C; Cea M; Bonello F; Rota-Scalabrini D; Patriarca F; Capra A; Petrucci MT; Ciccone G; Liberati AM; Pescosta N; Bringhen S; Falcone AP; Mina R;

Isatuximab for relapsed/refractory multiple myeloma: review of key subgroup analyses from the Phase III ICARIA-MM study. in Future oncology (London, England) / Future Oncol. 2021 Dec;17(34):4797-4812. doi: 10.2217/fon-2021-0568. Epub 2021 Sep 15.
2021
AOU Città della Salute di Torino

Richardson PG; Harrison SJ; Bringhen S; Schjesvold F; Yong K; Campana F; Le-Guennec S; Macé S; Dimopoulos MA;

Octogenarian newly diagnosed multiple myeloma patients without geriatric impairments: the role of age >80 in the IMWG frailty score. in Blood cancer journal / Blood Cancer J. 2021 Apr 12;11(4):73. doi: 10.1038/s41408-021-00464-w.
2021
ASL Torino 4
AOU San Luigi di Orbassano
AOU Città della Salute di Torino

Hájek R; Sonneveld P; Boccadoro M; Musto P; Guglielmelli T; Di Raimondo F; Corradini P; Aitoro G; Benevolo G; Giuliani N; Patriarca F; Bonello F; de Fabritiis P; Innao V; Zambello R; Cascavilla N; Derudas D; Capra A; Petrucci MT; Gaidano G; Offidani M; Liberati AM; Larocca A; D'Agostino M; Bringhen S;

Isatuximab plus pomalidomide and dexamethasone in elderly patients with relapsed/refractory multiple myeloma: ICARIA-MM subgroup analysis. in Haematologica / Haematologica. 2021 Apr 1;106(4):1182-1187. doi: 10.3324/haematol.2020.253450.
2021
AOU Città della Salute di Torino

Schjesvold FH; Richardson PG; Facon T; Alegre A; Spencer A; Jurczyszyn A; Sunami K; Frenzel L; Min CK; Guillonneau S; Lin PL; Le-Guennec S; Campana F; van de Velde H; Bensfia S; Bringhen S;

2021
AOU Città della Salute di Torino

Astarita A; Mingrone G; Airale L; Vallelonga F; Covella M; Catarinella C; Cesareo M; Bruno G; Leone D; Giordana C; Cetani G; Salvini M; Gay F; Bringhen S; Rabbia F; Veglio F; Milan A;

2021
AOU Città della Salute di Torino

Mina R; Bonello F; Petrucci MT; Liberati AM; Conticello C; Ballanti S; Musto P; Olivieri A; Benevolo G; Capra A; Gilestro M; Galieni P; Cavo M; Siniscalchi A; Palumbo A; Montefusco V; Gaidano G; Omedé P; Boccadoro M; Bringhen S;

Effects of Carfilzomib Therapy on Left Ventricular Function in Multiple Myeloma Patients. in Frontiers in cardiovascular medicine / Front Cardiovasc Med. 2021 Apr 21;8:645678. doi: 10.3389/fcvm.2021.645678. eCollection 2021.
2021
AOU Città della Salute di Torino

Veglio F; Bringhen S; Gay F; Cetani G; Salvini M; Catarinella C; Avenatti E; Leone D; Bruno G; Crea T; Cesareo M; Maffei I; Airale L; Astarita A; Mingrone G; Vallelonga F; Milan A;

2021
AOU Città della Salute di Torino

Fonio P; Bringhen S; Gianusso L; Strazzarino GA; Serafini A; Santonocito A; Oronzio M; Mina R; Rampado O; Guarnaccia C; Tore D; Depaoli A;

Melflufen: A Peptide-Drug Conjugate for the Treatment of Multiple Myeloma. in Journal of clinical medicine / J Clin Med. 2020 Sep 27;9(10):3120. doi: 10.3390/jcm9103120.
2020
AOU Città della Salute di Torino

Mateos MV; Bladé J; Bringhen S; Ocio EM; Efebera Y; Pour L; Gay F; Sonneveld P; Gullbo J; Richardson PG;

Early Relapse Risk in Patients with Newly Diagnosed Multiple Myeloma Characterized by Next-generation Sequencing. in Clinical cancer research : an official journal of the American Association for Cancer Research / Clin Cancer Res. 2020 Sep 15;26(18):4832-4841. doi: 10.1158/1078-0432.CCR-20-0951. Epub 2020 Jul 2.
2020
AOU Città della Salute di Torino

D'Agostino M; Zaccaria GM; Ziccheddu B; Rustad EH; Genuardi E; Capra A; Oliva S; Auclair D; Yesil J; Colucci P; Keats JJ; Gambella M; Bringhen S; Larocca A; Boccadoro M; Bolli N; Maura F; Gay F; D'Agostino M; Zaccaria GM; Ziccheddu B; Rustad EH; Genuardi E; Capra A; Oliva S; Auclair D; Yesil J; Colucci P; Keats JJ; et alii...

New drugs in early development for treating multiple myeloma: all that glitters is not gold. in Expert opinion on investigational drugs / Expert Opin Investig Drugs. 2020 Sep;29(9):989-1004. doi: 10.1080/13543784.2020.1772753. Epub 2020 S
2020
AOU Città della Salute di Torino

Bertamini L; Bonello F; Boccadoro M; Bringhen S;

Efficacy and safety of carfilzomib-based regimens in frail patients with relapsed and/or refractory multiple myeloma. in Blood advances / Blood Adv. 2020 Nov 10;4(21):5449-5459. doi: 10.1182/bloodadvances.2020001965.
2020
AOU Città della Salute di Torino

Facon T; Niesvizky R; Mateos MV; Siegel D; Rosenbaum C; Bringhen S; Weisel K; Ho PJ; Ludwig H; Kumar S; Wang K; Obreja M; Yang Z; Klippel Z; Mezzi K; Goldrick A; Tekle C; Dimopoulos MA;

Monoclonal Antibodies to Treat Multiple Myeloma: A Dream Come True. in International journal of molecular sciences / Int J Mol Sci. 2020 Nov 1;21(21):8192. doi: 10.3390/ijms21218192.
2020
AOU Città della Salute di Torino

D'Agostino M; Innorcia S; Boccadoro M; Bringhen S;

Melflufen plus dexamethasone in relapsed and refractory multiple myeloma (O-12-M1): a multicentre, international, open-label, phase 1-2 study. in The Lancet. Haematology / Lancet Haematol. 2020 May;7(5):e395-e407. doi: 10.1016/S2352-3026(20)30044-2. Epub 2020 Mar 23.
2020
AOU Città della Salute di Torino

Anderson K; Nordström E; Chauhan D; Byrne C; Zubair H; Paba-Prada C; Reeves B; Mellqvist UH; Plesner T; Voorhees P; Bringhen S; Richardson PG; Harmenberg J; Palumbo A; Sonneveld P;

Caring for older adults with multiple myeloma during the COVID-19 Pandemic: Perspective from the International Forum for Optimizing Care of Older Adults with Myeloma. in Journal of geriatric oncology / J Geriatr Oncol. 2020 Jun;11(5):764-768. doi: 10.1016/j.jgo.2020.04.008. Epub 2020 Apr 17.
2020
AOU Città della Salute di Torino

Mian H; Grant SJ; Engelhardt M; Pawlyn C; Bringhen S; Zweegman S; Stege CAM; Rosko AE; von Lilienfeld-Toal M; Wildes TM;

Lenalidomide-based induction and maintenance in elderly newly diagnosed multiple myeloma patients: updated results of the EMN01 randomized trial. in Haematologica / Haematologica. 2020 Jul;105(7):1937-1947. doi: 10.3324/haematol.2019.226407. Epub 2019 Oct 3.
2020
ASL Torino 4
AOU Città della Salute di Torino

Boccadoro M; Larocca A; Falco P; Hájek R; Palumbo A; Marasca R; Cellini C; Petrucci MT; Tosi P; Gentile M; Baldini L; Santoro A; Aquino S; Poggiu M; Pavone V; Gazzera G; De Rosa L; Grasso M; Rota-Scalabrini D; Pezzatti S; Spada S; Ballanti S; Pescosta N; Paris L; D'Agostino M; Bringhen S;

The Role of Monoclonal Antibodies in the First-Line Treatment of Transplant-Ineligible Patients with Newly Diagnosed Multiple Myeloma. in Pharmaceuticals (Basel, Switzerland) / Pharmaceuticals (Basel). 2020 Dec 29;14(1):20. doi: 10.3390/ph14010020.
2020
AO Cuneo
AOU Città della Salute di Torino

Bringhen S; Boccadoro M; Castellino A; Celeghini I; Grasso M; D'Agostino M; Bonello F;

Ixazomib as Postinduction Maintenance for Patients With Newly Diagnosed Multiple Myeloma Not Undergoing Autologous Stem Cell Transplantation: The Phase III TOURMALINE-MM4 Trial. in Journal of clinical oncology : official journal of the American Society of Clinical Oncology / J Clin Oncol. 2020 Dec 1;38(34):4030-4041. doi: 10.1200/JCO.20.02060. Epub 2020 Oct 6.
2020
AOU Città della Salute di Torino

Labotka R; Vorog A; Morgan G; Mateos MV; Iida S; Leleu X; Katodritou E; Chng WJ; Beksac M; Bringhen S; Garg M; Hájek R; Oriol A; Quach H; Špi?ka I; Dimopoulos MA; Wang B; Palumbo A; Lonial S;

2020
AOU Città della Salute di Torino

Palumbo A; De Paoli L; Romano A; Zambello R; Falcone AP; Giuliani N; Paris L; Fraticelli V; Amico V; Musto P; Bernardini A; Cangiolosi C; Innao V; Oddolo D; Benevolo G; Spada S; Evangelista A; Patriarca F; Ledda A; Liberati AM; Offidani M; Mina R; Larocca A; Montefusco V; Hájek R; Boccadoro M; Bringhen S;

2019
AOU Città della Salute di Torino

Bruno G; Bringhen S; Maffei I; Iannaccone A; Crea T; Ravera A; Astarita A; Vallelonga F; Salvini M; Gay F; Veglio F; Milan A;

2019
AOU Città della Salute di Torino

Boccadoro M; Dimopoulos MA; Caers J; Gramatzki M; Auner HW; Ludwig H; Driessen C; Cavo M; Goldschmidt H; Terpos E; Zweegman S; Offidani M; Larocca A; Gay F; Wäsch R; Ferri C; D'Agostino M; Milan A; Bringhen S; Einsele H; Sonneveld P; Engelhardt M;

2019
AO Ordine Mauriziano
AOU San Luigi di Orbassano
AOU Città della Salute di Torino

Ria R; Boccadoro M; Vacca A; Dammacco F; Petrucci MT; Musto P; Montefusco V; Rizzo M; Falcone AP; Grasso M; Gottardi D; Leonardi G; Baldini L; Benevolo G; Callea V; Patriarca F; Guglielmelli T; Nozzoli C; Larocca A; Offidani M; De Paoli L; Martino E; Bringhen S; Palumbo A; Omedè P; Giuliani N; Saltarella I; Terragna C; Morabito F; et alii...

Approach to the Older Adult With Multiple Myeloma. in American Society of Clinical Oncology educational book. American Society of Clinical Oncology. Annual Meeting / Am Soc Clin Oncol Educ Book. 2019 Jan;39:500-518. doi: 10.1200/EDBK_239067. Epub 2019 May 17.
2019
AOU Città della Salute di Torino

Mina R; Bringhen S; Wildes TM; Zweegman S; Rosko AE;

2019
AOU Città della Salute di Torino

Caravita T; Reddiconto G; Fragasso A; Di Renzo N; Genuardi M; Bringhen S; Mansueto G; D'Arena G; Pietrantuono G; Villani O; Gagliardi A; Mastrullo L; Catalano L; Salvatore D; Ria R; Conticello C; Di Raimondo F; Cesini L; Petrucci MT; Falcone A; Cascavilla N; Simeon V; Musto P; Scapicchio D; Marziano G; Boccadoro M; Mangiacavalli S; Corso A; Musto P; et alii...

Once-weekly versus twice-weekly carfilzomib in patients with newly diagnosed multiple myeloma: a pooled analysis of two phase I/II studies. in Haematologica / Haematologica. 2019 Aug;104(8):1640-1647. doi: 10.3324/haematol.2018.208272. Epub 2019 Feb 7.
2019
AOU Città della Salute di Torino

Palumbo A; Di Raimondo F; Montefusco V; Di Toritto TC; Cavo M; Galieni P; Ponticelli E; Benevolo G; Spada S; Offidani M; Musto P; Ballanti S; Gaidano G; Petrucci MT; Mina R; Bringhen S; Boccadoro M; Larocca A;

Clinical and Pharmacologic Features of Monoclonal Antibodies and Checkpoint Blockade Therapy in Multiple Myeloma. in Current medicinal chemistry / Curr Med Chem. 2019;26(32):5968-5981. doi: 10.2174/0929867325666180514114806.
2019
AOU Città della Salute di Torino

D'Agostino M; Gazzera G; Cetani G; Bringhen S; Boccadoro M; Gay F;

Determining treatment intensity in elderly patients with multiple myeloma. in Expert review of anticancer therapy / Expert Rev Anticancer Ther. 2018 Sep;18(9):917-930. doi: 10.1080/14737140.2018.1496823. Epub 2018 Ju
2018
AOU Città della Salute di Torino

Salvini M; D'Agostino M; Bonello F; Boccadoro M; Bringhen S; Salvini M; D'Agostino M; Bonello F; Boccadoro M; Bringhen S;

2018
AOU Città della Salute di Torino

Bringhen S; Milan A; Ferri C; Wäsch R; Gay F; Larocca A; Salvini M; Terpos E; Goldschmidt H; Cavo M; Petrucci MT; Ludwig H; Auner HW; Caers J; Gramatzki M; Boccadoro M; Einsele H; Sonneveld P; Engelhardt M; Bringhen S; Milan A; Ferri C; Wäsch R; Gay F; Larocca A; Salvini M; Terpos E; Goldschmidt H; Cavo M; et alii...

Maintenance Treatment and Survival in Patients With Myeloma: A Systematic Review and Network Meta-analysis. in JAMA oncology / JAMA Oncol. 2018 Oct 1;4(10):1389-1397. doi: 10.1001/jamaoncol.2018.2961.
2018
AOU Città della Salute di Torino

Gay F; Jackson G; Rosiñol L; Holstein SA; Moreau P; Spada S; Davies F; Lahuerta JJ; Leleu X; Bringhen S; Evangelista A; Hulin C; Panzani U; Cairns DA; Di Raimondo F; Macro M; Liberati AM; Pawlyn C; Offidani M; Spencer A; Hájek R; Terpos E; Morgan GJ; Bladé J; Sonneveld P; San-Miguel J; McCarthy PL; Ludwig H; Boccadoro M; et alii...

Early mortality in myeloma patients treated with first-generation novel agents thalidomide, lenalidomide, bortezomib at diagnosis: A pooled analysis. in Critical reviews in oncology/hematology / Crit Rev Oncol Hematol. 2018 Oct;130:27-35. doi: 10.1016/j.critrevonc.2018.07.003. Epub 2018 Jul 18.
2018
AOU Città della Salute di Torino

Bringhen S; Offidani M; Palmieri S; Pisani F; Rizzi R; Spada S; Evangelista A; Di Renzo N; Musto P; Marcatti M; Vallone R; Storti S; Bernardini A; Centurioni R; Aitini E; Palmas A; Annibali O; Angelucci E; Ferrando P; Baraldi A; Rocco S; Andriani A; Siniscalchi A; De Stefano V; Meneghini V; Palumbo A; Grammatico S; Boccadoro M; Larocca A; et alii...

Updated results of a phase 2 study of panobinostat combined with melphalan, thalidomide and prednisone (MPT) in relapsed/refractory multiple myeloma. in Leukemia & lymphoma / Leuk Lymphoma. 2018 May;59(5):1271-1273. doi: 10.1080/10428194.2017.1372575. Epub 2017 Sep 11.
2018
AOU Città della Salute di Torino

Bringhen S; Ballanti S; Pulini S; Liberati AM; Offidani M; Corvatta L;

Evaluation of Cardiovascular Toxicity Associated with Treatments Containing Proteasome Inhibitors in Multiple Myeloma Therapy. in High blood pressure & cardiovascular prevention : the official journal of the Italian Society of Hypertension / High Blood Press Cardiovasc Prev. 2018 Jun;25(2):209-218. doi: 10.1007/s40292-018-0256-1. Epub 2018
2018
AOU Città della Salute di Torino

Iannaccone A; Bruno G; Ravera A; Gay F; Salvini M; Bringhen S; Sabia L; Avenatti E; Veglio F; Milan A;

Impact of New Drugs on the Long-Term Follow-Up of Upfront Tandem Autograft-Allograft in Multiple Myeloma. in Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation / Biol Blood Marrow Transplant. 2018 Jan;24(1):189-193. doi: 10.1016/j.bbmt.2017.09.017. Epub 2017 Oct
2018
AOU Città della Salute di Torino

Ciccone G; Boccadoro M; Fanin R; Mordini N; Bringhen S; Omedé P; Maffini E; Zallio F; Brunello L; Festuccia M; Carnevale-Schianca F; Pini M; Sorasio R; Patriarca F; Evangelista A; Giaccone L; Bruno B;

Once-weekly carfilzomib, pomalidomide, and low-dose dexamethasone for relapsed/refractory myeloma: a phase I/II study. in Leukemia / Leukemia. 2018 Aug;32(8):1803-1807. doi: 10.1038/s41375-018-0024-1. Epub 2018 Jan 30.
2018
AOU Città della Salute di Torino

Palumbo A; Lombardo A; Bertazzoni P; Rossi G; De Paoli L; Fanin R; Troia R; Patriarca F; Gaidano G; Belotti A; Spada S; Liberati AM; Cafro AM; Mina R; Bringhen S; Sonneveld P; Boccadoro M; Bringhen S; Mina R; Cafro AM; Liberati AM; Spada S; Belotti A; Gaidano G; Patriarca F; Troia R; Fanin R; De Paoli L; Rossi G; et alii...

Patient-centered practice in elderly myeloma patients: an overview and consensus from the European Myeloma Network (EMN). in Leukemia / Leukemia. 2018 Aug;32(8):1697-1712. doi: 10.1038/s41375-018-0142-9. Epub 2018 Apr 25.
2018
AOU Città della Salute di Torino

Einsele H; Boccadoro M; Dimopoulos MA; Offidani M; Gramatzki M; Auner HW; Caers J; Bringhen S; Ludwig H; Straka C; Cavo M; Gay F; Goldschmidt H; Scheubeck S; D'Agostino M; Wäsch R; Terpos E; Zweegman S; Dold SM; Larocca A; Sonneveld P; Engelhardt M; Larocca A; Dold SM; Zweegman S; Terpos E; Wäsch R; D'Agostino M; Scheubeck S; et alii...

Treatment Intensification With Autologous Stem Cell Transplantation and Lenalidomide Maintenance Improves Survival Outcomes of Patients With Newly Diagnosed Multiple Myeloma in Complete Response. in Clinical lymphoma, myeloma & leukemia / Clin Lymphoma Myeloma Leuk. 2018 Aug;18(8):533-540. doi: 10.1016/j.clml.2018.05.019. Epub 2018 May 2
2018
AOU San Luigi di Orbassano
AOU Città della Salute di Torino

Bringhen S; Boccadoro M; Spencer A; Hájek R; Nagler A; Calafiore V; Falcone AP; Palumbo A; Benevolo G; Zambello R; Mannina D; Gamberi B; Baldini L; Guglielmelli T; Musto P; Malfitano A; Pescosta N; Ria R; De Paoli L; Cerrato C; Patriarca F; Spada S; Corradini P; Mina R; Petrucci MT; Mina R; Petrucci MT; Corradini P; Spada S; et alii...

Phase 1/2 study of weekly carfilzomib, cyclophosphamide, dexamethasone in newly diagnosed transplant-ineligible myeloma. in Leukemia / Leukemia. 2018 Apr;32(4):979-985. doi: 10.1038/leu.2017.327. Epub 2017 Nov 16.
2018
AOU Città della Salute di Torino
AOU Novara

Boccadoro M; Sonneveld P; Corradini P; Palumbo A; Gaidano G; Ballanti S; Petrucci MT; Offidani M; Musto P; De Angelis C; Esma F; Muccio VE; Liberati AM; Galieni P; Grammatico S; Montefusco V; De Paoli L; D'Agostino M; Bringhen S;

Emerging drugs and combinations to treat multiple myeloma. in Oncotarget / Oncotarget. 2017 Jul 15;8(36):60656-60672. doi: 10.18632/oncotarget.19269. eCollection 2017 Sep 1.
2017
AOU Città della Salute di Torino

Larocca A; Mina R; Gay F; Bringhen S; Boccadoro M;

Systemic virotherapy for multiple myeloma. in Expert opinion on biological therapy / Expert Opin Biol Ther. 2017 Nov;17(11):1375-1387. doi: 10.1080/14712598.2017.1364359. Epub 2017 Aug
2017
AOU Città della Salute di Torino

Oliva S; Gambella M; Boccadoro M; Bringhen S;

Salvage therapy in first relapse: a retrospective study in a large patient population with multiple myeloma. in European journal of haematology / Eur J Haematol. 2017 Mar;98(3):289-295. doi: 10.1111/ejh.12834. Epub 2017 Jan 5.
2017
AOU Città della Salute di Torino

Offidani M; Corvatta L; Bringhen S; Gentili S; Troia R; Maracci L; Larocca A; Gay F; Leoni P; Boccadoro M;

2017
AOU Città della Salute di Torino

Gentile M; Magarotto V; Offidani M; Musto P; Bringhen S; Teresa Petrucci M; Gay F; Larocca A; Uccello G; Petrungaro A; Vigna E; Greco R; Grazia Recchia A; Tripepi G; Ria R; Di Raimondo F; Palumbo A; Morabito F;

How is patient care for multiple myeloma advancing? in Expert review of hematology / Expert Rev Hematol. 2017 Jun;10(6):551-561. doi: 10.1080/17474086.2017.1326814. Epub 2017 May 19.
2017
AOU Città della Salute di Torino

Genadieva Stavric S; Bonello F; Bringhen S; Boccadoro M; Larocca A;

Triplet vs doublet lenalidomide-containing regimens for the treatment of elderly patients with newly diagnosed multiple myeloma. in Blood / Blood. 2016 Mar 3;127(9):1102-8. doi: 10.1182/blood-2015-08-662627. Epub 2016 Jan 4.
2016
AOU San Luigi di Orbassano
AOU Città della Salute di Torino
AOU Novara

Palumbo A; Boccadoro M; Hajek R; Montefusco V; Guglielmelli T; Ledda A; Liberati AM; Ruggeri M; Zambello R; Maisnar V; Conticello C; Pulini S; Ciccone G; Bernardini A; Giuliani N; Musolino C; Gentili S; Pietrantuono G; Falcone AP; De Paoli L; Mina R; Patriarca F; Benevolo G; Offidani M; Bringhen S; Magarotto V;

A phase 2 study of three low-dose intensity subcutaneous bortezomib regimens in elderly frail patients with untreated multiple myeloma. in Leukemia / Leukemia. 2016 Jun;30(6):1320-6. doi: 10.1038/leu.2016.36. Epub 2016 Feb 22.
2016
AOU San Luigi di Orbassano
AOU Città della Salute di Torino
AOU Novara

Palumbo A; Sonneveld P; Offidani M; Boccadoro M; Musolino C; De Paoli L; Conticello C; Nozzoli C; Aghemo E; Derudas D; Genuardi M; Guglielmelli T; Carella AM; Ponticelli E; Spada S; Vincelli ID; De Rosa L; Omedé P; Morabito F; Montefusco V; Passera R; Benevolo G; Liberati AM; Falcone AP; Caravita T; Villani O; Oliva S; Petrucci MT; Bringhen S; et alii...

Strategy for the treatment of multiple myeloma utilizing monoclonal antibodies: A new era begins. in Leukemia & lymphoma / Leuk Lymphoma. 2016;57(3):537-56. doi: 10.3109/10428194.2015.1102245. Epub 2015 Dec 23.
2016
AOU Città della Salute di Torino

Palumbo A; Bringhen S; Bonello F; Salvini M; Magarotto V;

Geriatric assessment predicts survival and toxicities in elderly myeloma patients: an International Myeloma Working Group report. in Blood / Blood. 2015 Mar 26;125(13):2068-74. doi: 10.1182/blood-2014-12-615187. Epub 2015 Jan 27.
2015
AOU Città della Salute di Torino

Palumbo A; Bringhen S; Mateos MV; Larocca A; Facon T; Kumar SK; Offidani M; McCarthy P; Evangelista A; Lonial S; Zweegman S; Musto P; Terpos E; Belch A; Hajek R; Ludwig H; Stewart AK; Moreau P; Anderson K; Einsele H; Durie BG; Dimopoulos MA; Landgren O; San Miguel JF; Richardson P; Sonneveld P; Rajkumar SV;

2015
AOU Città della Salute di Torino

Musto P; Simeon V; Grossi A; Gay F; Bringhen S; Larocca A; Guariglia R; Pietrantuono G; Villani O; D'Arena G; Cuomo C; Musto C; Morabito F; Petrucci MT; Offidani M; Zamagni E; Tacchetti P; Conticello C; Milone G; Palumbo A; Cavo M; Boccadoro M;

Circulating miRNA markers show promise as new prognosticators for multiple myeloma. in Leukemia / Leukemia. 2014 Sep;28(9):1922-6. doi: 10.1038/leu.2014.155. Epub 2014 May 12.
2014
AOU Città della Salute di Torino

Rocci A; Hofmeister CC; Geyer S; Stiff A; Gambella M; Cascione L; Guan J; Benson DM; Efebera YA; Talabere T; Dirisala V; Smith EM; Omedè P; Isaia G; De Luca L; Rossi D; Gentili S; Uccello G; Consiglio J; Ria R; Benevolo G; Bringhen S; Callea V; Weiss B; Ferro A; Magarotto V; Alder H; Byrd JC; Boccadoro M; et alii...

Current Phase II investigational proteasome inhibitors for the treatment of multiple myeloma. in Expert opinion on investigational drugs / Expert Opin Investig Drugs. 2014 Sep;23(9):1193-209. doi: 10.1517/13543784.2014.920821. Epub 2014 Ju
2014
AOU Città della Salute di Torino

Bringhen S; Gay F; Donato F; Troia R; Mina R; Palumbo A;

Chromosome 1 abnormalities in elderly patients with newly diagnosed multiple myeloma treated with novel therapies. in Haematologica / Haematologica. 2014 Oct;99(10):1611-7. doi: 10.3324/haematol.2014.103853. Epub 2014 Jul 11.
2014
AOU Città della Salute di Torino

Caltagirone S; Ruggeri M; Aschero S; Gilestro M; Oddolo D; Gay F; Bringhen S; Musolino C; Baldini L; Musto P; Petrucci MT; Gaidano G; Passera R; Bruno B; Palumbo A; Boccadoro M; Omedè P;

Bortezomib-melphalan-prednisone-thalidomide followed by maintenance with bortezomib-thalidomide compared with bortezomib-melphalan-prednisone for initial treatment of multiple myeloma: updated follow-up and improved survival. in Journal of clinical oncology : official journal of the American Society of Clinical Oncology / J Clin Oncol. 2014 Mar 1;32(7):634-40. doi: 10.1200/JCO.2013.52.0023. Epub 2014 Jan 21.
2014
AO Ordine Mauriziano
AOU San Luigi di Orbassano
AOU Città della Salute di Torino

Ria R; Offidani M; Gaidano G; Passera R; Nozzoli C; Guglielmelli T; Mina R; Morabito F; Marasca R; Omedé P; Bringhen S; Larocca A; Rossi D; Di Raimondo F; Magarotto V; Patriarca F; Levi A; Benevolo G; Vincelli ID; Grasso M; Franceschini L; Gottardi D; Zambello R; Montefusco V; Falcone AP; Palumbo A; Petrucci MT; Musto P; Boccadoro M; et alii...

Second primary malignancies with lenalidomide therapy for newly diagnosed myeloma: a meta-analysis of individual patient data. in The Lancet. Oncology / Lancet Oncol. 2014 Mar;15(3):333-42. doi: 10.1016/S1470-2045(13)70609-0. Epub 2014 Feb 11.
2014
AOU Città della Salute di Torino

Palumbo A; Bringhen S; Kumar SK; Lupparelli G; Usmani S; Waage A; Larocca A; van der Holt B; Musto P; Offidani M; Petrucci MT; Evangelista A; Zweegman S; Nooka AK; Spencer A; Dimopoulos MA; Hajek R; Cavo M; Richardson P; Lonial S; Ciccone G; Boccadoro M; Anderson K; Barlogie B; Sonneveld P; McCarthy PL;

Carfilzomib, cyclophosphamide, and dexamethasone in patients with newly diagnosed multiple myeloma: a multicenter, phase 2 study. in Blood / Blood. 2014 Jul 3;124(1):63-9. doi: 10.1182/blood-2014-03-563759. Epub 2014 May 22.
2014
AOU Città della Salute di Torino
AOU Novara

Boccadoro M; Caravita T; Tacchetti P; Oliva S; Montefusco V; Genuardi M; Benevolo G; Ciccone G; Gentilini F; Offidani M; Omedé P; Boccadifuoco L; Musto P; Magarotto V; Rossi D; Conticello C; Larocca A; Petrucci MT; Bringhen S; Sonneveld P; Palumbo A;

Lenalidomide and low-dose dexamethasone for newly diagnosed primary plasma cell leukemia. in Leukemia / Leukemia. 2014 Jan;28(1):222-5. doi: 10.1038/leu.2013.241. Epub 2013 Aug 20.
2014
AOU Città della Salute di Torino

Musto P; Simeon V; Martorelli MC; Petrucci MT; Cascavilla N; Di Raimondo F; Caravita T; Morabito F; Offidani M; Olivieri A; Benevolo G; Mina R; Guariglia R; D'Arena G; Mansueto G; Filardi N; Nobile F; Levi A; Falcone A; Cavalli M; Pietrantuono G; Villani O; Bringhen S; Omedè P; Lerose R; Agnelli L; Todoerti K; Neri A; Boccadoro M; et alii...

Monoclonal antibodies currently in Phase II and III trials for multiple myeloma. in Expert opinion on biological therapy / Expert Opin Biol Ther. 2014 Aug;14(8):1127-44. doi: 10.1517/14712598.2014.908848. Epub 2014 Apr 21.
2014
AOU Città della Salute di Torino

Donato F; Gay F; Bringhen S; Troia R; Palumbo A;

Pomalidomide, cyclophosphamide, and prednisone for relapsed/refractory multiple myeloma: a multicenter phase 1/2 open-label study. in Blood / Blood. 2013 Oct 17;122(16):2799-806. doi: 10.1182/blood-2013-03-488676. Epub 2013 Aug 16.
2013
AOU Città della Salute di Torino
ASL Vercelli

Larocca A; Montefusco V; Bringhen S; Rossi D; Crippa C; Mina R; Galli M; Marcatti M; La Verde G; Giuliani N; Magarotto V; Guglielmelli T; Rota-Scalabrini D; Omedé P; Santagostino A; Baldi I; Carella AM; Boccadoro M; Corradini P; Palumbo A;

The mechanism of action, pharmacokinetics, and clinical efficacy of carfilzomib for the treatment of multiple myeloma. in Expert opinion on drug metabolism & toxicology / Expert Opin Drug Metab Toxicol. 2013 Oct;9(10):1371-9. doi: 10.1517/17425255.2013.817556. Epub 2013
2013
AOU Città della Salute di Torino

Pautasso C; Bringhen S; Cerrato C; Magarotto V; Palumbo A;

Pharmacokinetic evaluation of pomalidomide for the treatment of myeloma. in Expert opinion on drug metabolism & toxicology / Expert Opin Drug Metab Toxicol. 2013 Nov;9(11):1517-27. doi: 10.1517/17425255.2013.827169. Epub 2013
2013
AOU Città della Salute di Torino

Gay F; Mina R; Troia R; Bringhen S;

Age and organ damage correlate with poor survival in myeloma patients: meta-analysis of 1435 individual patient data from 4 randomized trials. in Haematologica / Haematologica. 2013 Jun;98(6):980-7. doi: 10.3324/haematol.2012.075051. Epub 2013 Feb 26.
2013
AOU Città della Salute di Torino

Bringhen S; Mateos MV; Zweegman S; Larocca A; Falcone AP; Oriol A; Rossi D; Cavalli M; Wijermans P; Ria R; Offidani M; Lahuerta JJ; Liberati AM; Mina R; Callea V; Schaafsma M; Cerrato C; Marasca R; Franceschini L; Evangelista A; Teruel AI; van der Holt B; Montefusco V; Ciccone G; Boccadoro M; San Miguel J; Sonneveld P; Palumbo A;